Surge Therapeutics has raised money to take its extended-release biodegradable hydrogel into the clinic, reeling in $26 million to test its belief that implanting the scaffolds after surgery will improve outcomes in solid tumor patients.
Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery
Every year, millions of cancer patients undergo surgery to get their tumors removed. But while resection can stave off cancer for some time, as many as 40% of patients would eventually see their cancer return — and succumb to the disease.
Post-surgical recurrence and metastasis account for 90 percent of cancer-related deaths, something Dr. Michael Goldberg, founder and CEO of newly debuted SURGE Therapeutics, knows all too well.
Surge Therapeutics Inc. landed $26 million in funding through a series A fundraising round to accelerate development of its intraoperative immunotherapy hydrogel.
Cancers are like garden weeds. Even after the surgical removal of a tumor, cancer-cell stragglers can grow back and overrun the body. Surgery is the most common intervention for tumors, but it’s by no means a cure—about 40% of the 9 million people around the world who undergo the procedure every year experience a cancer comeback within 5 years.
A scientist who trained under renowned chemical engineer Bob Langer and Nobel Prize-winning Biogen Inc. co-founder Phillip Sharp has ideas about how to transform cancer treatment.
Surge Therapeutics' hydrogel is engineered to deliver a cancer immunotherapy. Rather than replace surgery, CEO Michael Goldberg says the hydrogel could supplement this standard of care for solid tumors. The startup's Series A financing will support the technology's first test in humans.
SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery
Funding will be used to accelerate development of the SURGE™ intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its first two programs.